Are bispecific therapies being combined with each other to treat multiple myeloma? 

Several active clinical trials are testing the combination of bispecific antibodies with one another, provided that they have different targets. One of the emerging combinations that seem to have extreme success is the combination of talquetamab and teclistamab. 

Combining bispecifics in clinical trials 

These clinical trials will test for effective combinations, best dosing amounts, side effect profiles, and more. There are trials for active myeloma patients and a few for those with high-risk smoldering myeloma.

You can look at what active clinical trials are currently recruiting participants here: HealthTree Myeloma Clinical Trials

Some examples (as of July 2024) include: 

• NCT04586426: talquetamab and teclistamab 
• NCT06208150: talquetamab and teclistamab versus talquetamab and other anti-myeloma drugs